EXPORT CITATION

Chapter-53 New and Future Anti- Tuberculosis Drugs

BOOK TITLE: Practical Approach to Tuberculosis Management

Author
1. Bedi Rajinder Singh
ISBN
9788180617676
DOI
10.5005/jp/books/10639_53
Edition
1/e
Publishing Year
2006
Pages
14
Author Affiliations
1. Bedi Nursing Home, Sher-e-Punjab Market, Patiala, Punjab, Bedi Clinic and Nursing Home, Sher-e-Punjab Market, Patiala, Punjab
Chapter keywords
New and future anti-tuberculosis drugs, Adjunctive therapy, Beta-lactamse, Clofazimine, Diaryquinolines, Fluoroquinolones, Multidrug-resistant tuberculosis, Mycobacterium tuberculosis, Need for new drugs, New anti-TB agents, Nitroimidazopyrans, Oxazolidinones, Pyrrole derivatives, Rifamycin derivatives, Tuberculosis (TB)

Abstract

To learn and understand pharmacokinetics and pharmacodynamics for the newer and future anti tuberculosis drugs. New anti-tuberculosis drugs are needed (a) to further shorten the duration of chemotherapy from present minimum of 6 months, (b) To improve the treatment of MDR TB and (c) To provide shorter and more effective treatment of latent tuberculosis infections (LTBI) which is important component of TB control strategy in developed countries with low incidence of tuberculosis. However, in most of the world, because of paucity of funds, LTBI is neither diagnosed, nor treated and is not a priority for controlling tuberculosis. A number of other compounds in late preclinical and early clinical development show great promise, constant and untiring efforts and funding are required, if promise of TB elimination or at least significant lessening of the global TB epidemic, is to be achieved.

Related Books

© 2019 Jaypee Brothers Medical Publishers (P) LTD.   |   All Rights Reserved